

## KARPAS 231 Human B-cell Leukaemia cell line

**KARPAS 231 Human B-cell Leukaemia cell line useful in oncology research, developed at the University of Cambridge.**

Cambridge Enterprise Limited is the exclusive licensor for the Karpas cell line portfolio. We have partnered with ECACC (The European Collection of Cell Cultures; a Public Health England Culture Collection) to manage distribution of the majority of these cells on our behalf. Enquires to either organisation are welcomed.

### References

1. E Nacheva, M J Dyer, P Fischer, G Stranks, J M Heward, R E Marcus, C Grace, A Karpas(05-01-1993) , C-MYC translocations in de novo B-cell lineage acute leukemias with t(14;18)(cell lines Karpas 231 and 353), <https://www.sciencedirect.com/science/article/pii/S0006497120813378?via%3Dihub>, 82, 231-240
2. S Galiègue Zouitina, S Quief, M P Hildebrand, C Denis, G Lecocq, M Collyn-d'Hooghe, C Bastard, M Yuille, M J Dyer, J P Kerckaert(10-04-1996) , <https://pubmed.ncbi.nlm.nih.gov/8618432/>, 4, 579-587
3. T G Willis, D M Jadayel, L J Coignet, M Abdul-Rauf, J G Treleaven, D Catovsky, M J Dyer(15-09-1997) , <https://pubmed.ncbi.nlm.nih.gov/9310498/>, <https://pubmed.ncbi.nlm.nih.gov/9310498/>, 90, 2456-2464

### Category

Monoclonal Hybridomas  
Cell Lines

### Learn more

